Drugs / SYN-010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT02493036 | Oct → Dec 2015 | irritable bowel syndrome | Theriva Biologics, Inc. | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02495623 Comparator | Jun → Oct 2015 | irritable bowel syndrome | Theriva Biologics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2020-10-02 | Theriva Biologics, Inc. | Results Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients therivabio.com ↗
Based on the review of the interim analysis, it was concluded that although SYN-010 was well-tolerated, it is unlikely to meet its primary objective by the time enrollment is completed. |
| 2016-05-23 | Theriva Biologics, Inc. | Results Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) therivabio.com ↗
Data from both trials were presented by Mark Pimentel, MD, FRCP(C), Director of the GI Motility Program and Laboratory at Cedars-Sinai, during a poster session yesterday at Digestive Disease Week® (DDW® 2016) in San Diego, CA. |
| 2016-01-19 | Theriva Biologics, Inc. | Results Synthetic Biologics Reports Positive Topline Data from Second Phase 2 Clinical Trial of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) therivabio.com ↗ |
| 2015-12-08 | Theriva Biologics, Inc. | Results Synthetic Biologics’ SYN-010 Lowered Breath Methane and Improved Stool Frequency in a Phase 2 Four Week Study in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) therivabio.com ↗ |
| 2015-10-20 | Theriva Biologics, Inc. | Results Synthetic Biologics’ Novel Irritable Bowel Syndrome with Constipation (IBS-C) Program Featured in American College of Gastroenterology Poster therivabio.com ↗
Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced that experimental results supporting the proposed therapeutic mode-of-action of SYN-010 in irritable bowel syndrome with constipation (IBS-C) were presented today in a poster at the American College of Gastroenterology (ACG) Annual Meeting in Honolulu, HI. |
| 2015-05-18 | Theriva Biologics, Inc. | Results Synthetic Biologics’ Novel SYN-010 Preclinical Data Featured in Digestive Disease Week® Poster therivabio.com ↗
The “Lovastatin Improves Stool Form in Methanobrevibacter smithii Colonized Rats with Constipation” poster summarized preclinical efficacy data that support advancing Synthetic Biologics’ novel SYN-010, toward the clinic. |
All press releases naming this drug 16 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYN-010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02495623 ↗ |